HIGH-VOLUME · SEX-BALANCED
mepolizumab Side Effects
mepolizumab (also sold as Nucala) is HIGH-VOLUME in this FAERS book #148 of 524 by FAERS report count. Signature opener: SEX-BALANCED - 68% of sex-coded reports are female (23,211 F / 11,025 M).
Data updated 2026-05-15
- 47,215
- FAERS reports
FAERS voluntary reports, 2008 to 2025. High volume tracks exposure and reporting culture; see methodology for de-dup rules.
mepolizumab reporting skew - 68% of sex-coded reports are female (23,211 F / 11,025 M). Volume band HIGH-VOLUME #148 of 524 by FAERS report count; caseload CASELOAD.
High-report extract for mepolizumab (Nucala): 47,215 FAERS rows (2008-2025). Top named reactions: ASTHMA, DYSPNOEA, WHEEZING. Outcome stamps DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED. FAERS is voluntary signal detection, not incidence.
Counts from the openFDA FAERS extract (2008–2025). Stamps CASELOAD · DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED.
ASTHMA leads 12,416 of 47,215 reports
Who reports · age peak 45-64 (SEX-BALANCED)
Sex coding · SEX-BALANCED
Age peak 45-64 (7,567 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death-mentioned subset is HEAVY here (3,552 reports, 7.5%). Top co-reported reactions in that subset - voluntary, not causal.
| Reaction | Reports |
|---|---|
| DEATH | 1,677 |
| PAIN | 719 |
| CONFUSIONAL STATE | 685 |
| MATERNAL EXPOSURE DURING PREGNANCY | 685 |
| PEMPHIGUS | 680 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 677 |
| INFUSION RELATED REACTION | 670 |
| CONDITION AGGRAVATED | 666 |
| SYNOVITIS | 664 |
| SYSTEMIC LUPUS ERYTHEMATOSUS | 654 |
| LUNG DISORDER | 649 |
| DYSPNOEA | 648 |
| WOUND | 647 |
| GASTROOESOPHAGEAL REFLUX DISEASE | 642 |
| PSORIATIC ARTHROPATHY | 642 |
| GLOSSODYNIA | 641 |
| RASH | 638 |
Reactions in Hospitalization Reports
Hospitalization is HEAVY (15,164, 32.1% of the book). Top reactions in those rows:
| Reaction | Reports |
|---|---|
| ASTHMA | 6,643 |
| DYSPNOEA | 5,330 |
| WHEEZING | 3,748 |
| PNEUMONIA | 2,743 |
| THERAPEUTIC PRODUCT EFFECT INCOMPLETE | 2,457 |
| LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES | 2,287 |
| COUGH | 2,205 |
| HOSPITALISATION | 1,977 |
| SLEEP DISORDER DUE TO A GENERAL MEDICAL CONDITION | 1,633 |
| CONDITION AGGRAVATED | 1,408 |
| PAIN | 1,386 |
| FATIGUE | 1,365 |
| MALAISE | 1,356 |
| OBSTRUCTIVE AIRWAYS DISORDER | 1,159 |
| LUNG DISORDER | 1,094 |
| HEADACHE | 1,087 |
| ASTHENIA | 1,003 |
How to read mepolizumab FAERS figures (CASELOAD · DEATH-HEAVY · HOSP-HEAVY)
FAERS holds 47,215 voluntary reports linked to mepolizumab (Nucala), 2008-2025. Death is listed on 3,552 (7.5%). Hospitalization appears on 15,164 (32.1%). Top co-reported indication: Product Used For Unknown Indication.
CASELOAD books overweight common drugs and loud reporting cultures; SEX-BALANCED is the page opener, not a per-patient risk.
Read with mepolizumab
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-HEAVY · HOSP-HEAVY stamps.
ABS(total_reports) peer at 47,426 FAERS cases (Δ 211 heavier vs mepolizumab); DEATH-HEAVY · HOSP-MID · FEMALE-LED vs this page's CASELOAD · DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED.
ABS(total_reports) peer at 46,939 FAERS cases (Δ 276 lighter vs mepolizumab); DEATH-RARE · HOSP-LIGHT · FEMALE-LED vs this page's CASELOAD · DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED.
ABS(total_reports) peer at 47,513 FAERS cases (Δ 298 heavier vs mepolizumab); DEATH-MARKED · HOSP-LIGHT · SEX-BALANCED vs this page's CASELOAD · DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED.
ABS(total_reports) peer at 47,788 FAERS cases (Δ 573 heavier vs mepolizumab); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's CASELOAD · DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 54.6 pp vs mepolizumab's DEATH-HEAVY): CASELOAD · HOSP-MID.
mepolizumab stamps DEATH-HEAVY · HOSP-HEAVY; FAERS outcome shares are signal-detection rates, not incidence. Read them next to caseload CASELOAD and the label guide.